Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: A new theranostic method combining xenografted biopsies with a mathematical model

Cancer Research

Volumn 68, Issue 21, 2008, Pages 9033-9040

  Gorelik, Boris ^a   Ziv, Irit ^a   Shohat, Revital ^a   Wick, Michael ^b   Hankins, W David ^c,d   Sidransky, David ^d   Agur, Zvia ^a,e  

^a Optimata Ltd   (Israel)

^b CTRC Institute for Drug Development   (United States)

^c New Hope Pharmaceuticals Inc   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Institute for Medical Biomathematics Isarel   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; SORAFENIB; SUNITINIB; VINCRISTINE;

ACCURACY; ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL INFILTRATION; CHEMOSENSITIVITY; CHONDROSARCOMA; COMBINATION CHEMOTHERAPY; COMPUTER SIMULATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; GENE EXPRESSION PROFILING; GROWTH CURVE; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MALE; MATHEMATICAL MODEL; MESENCHYME CHONDROSARCOMA; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PANCYTOPENIA; PREDICTION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE NEOPLASMS; CHONDROSARCOMA, MESENCHYMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MICE; MIDDLE AGED; MODELS, THEORETICAL; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 55349130623     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1723     Document Type: Article

References (49)

1. Pellitteri PK, Ferlito A, Fagan JJ, Suárez C, Devaney KO, Rinaldo A. Mesenchymal chondrosarcoma of the head and neck. Oral Oncol 2007;43:970-5.
2. Nakashima Y, Unni KK, Shives TC, Swee RG, Dahlin DC. Mesenchymal chondrosarcoma of bone and soft tissue. Areview of 111 cases. Cancer 1986;57:2444-53.
3. Zembutsu H, Ohnishi Y, Tsunoda T, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002;62:518-27.
4. Agur Z, Arakelyan L, Daugulis P, Ginosar Y. Hopf point analysis for angiogenesis models. Disc Cont Dyn Systems-Series B 2004;41:29-38.
5. Arakelyan L, Merbl Y, Daugulis P, et al. Multi-scale analysis of angiogenic dynamics and therapy. In: Preziosi L, editor. Cancer modelling and simulation. LLC (UK): CRC Press; 2003. p. 185-219.
6. Hart D, Shochat E, Agur Z. The growth law of primary breast cancer as inferred from mammography screening trials data. Br J Cancer 1998;78:382-7.
7. Agur Z, Arnon R, Schechter B. Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. Eur J Cancer 1992;28A:1085-90.
8. Agur Z. Resonance and anti-resonance in the design of chemotherapeutic protocols. Jour Theor Med 1998;1:237-45.
9. Shochat B, Hart D, Agur Z. Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols. J Math Models Methods Appl Sci 1994;94:599-615.
10. Ribba B, Marron K, Agur Z, Alarcon T, Maini PK. A mathematical model of doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results. Bull Math Biol 2005;67:79-99.
11. Harnevo LE, Agur Z. Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemother Pharmacol 1992;30:469-76.
12. Harnevo LE, Agur Z. Use of mathematical models for understanding the dynamics of gene amplification. Mutat Res 1993;292:17-24.
13. Mehr R, Agur Z. Bone marrow regeneration under cytotoxic drug regimens: behaviour ranging from homeostasis to unpredictability in a model for hemopoietic differentiation. Biosystems 1992;26:231-7.
14. Skomorovski K, Harpak H, Ianovski A, et al. New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model. Br J Haematol 2003;123:683-91.
15. Cappuccio A, Elishmereni M, Agur Z. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res 2006;66:7293-300.
16. Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother 2008;57:425-39.
17. Agur Z, Arnon R, Schechter B. Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs. Math Biosci 1988;92:1-15.
18. Vainstein V, Ginosar Y, Shoham M, Ranmar DO, Ianovski A, Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol 2005;234:311-27.
19. Begg AC. Principles and practices of the tumor growth delay assay. In: Kallman RF, editor. Rodent tumor models in experimental cancer therapy. New York: Pergamon; 1987. p. 114-21.
20. Arakelyan L, Merbl Y, Agur Z. Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids. Eur J Cancer 2005;41:159-67.
21. Ubezio P, Tagliabue G, Schechter B, Agur Z. Increasing 1-β-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. Cancer Res 1994;54:6446-51.
22. Mukherjee A, Chan S, Arakelyan L, et al. Virtual cancer patient (VCP) for treatment personalization: prediction accuracy in metastatic breast cancer (MBC) patients. NCRI Cancer Conference, 2006, Birmingham, United Kingdom.
23. Vainstein V, Ginosar Y, Shoham M, et al. Clinical validation of a physiologically-based computer model of human granulopoiesis and its use for improving cancer therapy by doxorubicin and granulocyte colony-stimulating factor (G-CSF). 48th Annual Meeting of the American Society of Hematology, 2006, Orlando, Florida.
24. Arakelyan L, Vainstein V, Agur Z. A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. Angiogenesis 2002;5:203-14.
25. Agur Z, Ziv I, Shohat R, et al. Using a novel computer technology for tailoring chemotherapeutic drug schedules to the individual patient. AACR Conference on Molecular Diagnostics in Cancer Therapeutic Development, September 12-15, 2006, Chicago, Illinois.
26. Song MK, Krutzsch H, Hankins WD, Richards WL, Thorgeirsson SS. Rapid determination of DNA synthesis in adherent cells grown in microtiter plates. Exp Cell Res 1985;156:271-6.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
28. Weisenthal LM, Dill PL, Kurnick NB, Lippman ME. Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 1983;43:258-64.
29. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591-8.
30. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
31. Cursiefen C, Hofmann-Rummelt C, Kuchle M, Schlotzer-Schrehardt U. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol 2003;87:101-6.
32. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 2004;25:536-42.
33. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
34. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;270:19761-6.
35. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001;280:C1367-74.
36. Danielsen T, Rofstad EK. The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts. Br J Cancer 2000;82:1528-34.
37. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 1997;94:8761-6.
38. Feng Y, vom Hagen F, Pfister F, et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 2007;97:99-108.
39. Hammes H-P, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004;53:1104-10.
40. Holford NH, Sheiner LB. Pharmacokinetic and pharmacodynamic modeling in vivo. Crit Rev Bioeng 1981;5:273-322.
41. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995;23:1008-21.
42. Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci 1996;85:232-9.
43. Kroese D, Porotsky S, Rubinstein R. The cross-entropy method for continuous multi-extremal optimization. Methodol Comput Appl Probab 2006;8:383-407.
44. Alexopoulos A, Karamouzis MV, Rigatos G. In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives. Semin Oncol 2004;31:25-30.
45. Dumez H, Louwerens M, Pawinsky A, et al. The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 2002;13:583-93.
46. Azuma M, Danenberg KD, Iqbal S, et al. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:214-8.
47. Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006;32:583-7.
48. Agur Z, Elishmereni M, Kogan Y, et al. Mathematical modeling as a new approach for improving the efficacy/ toxicity profile of drugs: the thrombocytopenia case study. In Gad SC, editor. Preclinical development handbook: ADME and biopharmaceutical properties. New Jersey: John Wiley and Sons; 2008. p. 1229-66.
49. Uma. Normal tissue protection in cancer therapy: progress and prospects. Acta Oncol 1998;37:247-52.